文献速递脊柱关节炎

症状持续时间是否影响中轴型脊柱关节炎的治疗反应?随机对照试验的荟萃分析

Does symptom duration impact on treatment response in axial spondyloarthritis? A meta-analysis of randomized controlled trials.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

该荟萃分析纳入11项bDMARD随机对照试验、共3272例中轴型脊柱关节炎患者,评估症状持续时间对治疗反应的影响。以2年为界,早期与 established 患者ASAS40应答的RR分别为2.04(95%CI 1.48-2.84)和2.28(95%CI 1.65-3.15),RRR为0.89(95%CI 0.63-1.26),无统计学显著性;其他结局及3-5年阈值亦无显著差异。

要点

  • 11项bDMARD随机对照试验共3272例axSpA患者纳入分析,无tsDMARD试验符合标准。
  • 2年阈值下早期axSpA的ASAS40应答RR为2.04(95%CI 1.48-2.84),established疾病为2.28(95%CI 1.65-3.15)。
  • RRR为0.89(95%CI 0.63-1.26),无统计学显著性;3-5年其他阈值亦无显著差异。

核心结论

  • 基于11项试验的荟萃分析,在2至5年各症状持续时间阈值下,bDMARD与安慰剂相比在症状持续时间较短与较长axSpA患者中的疗效无显著差异。

研究设计与样本

  • 系统文献综述(支持ASAS-EULAR管理推荐)识别比较b/tsDMARD与安慰剂的成人axSpA随机对照试验,纳入11项bDMARD随机对照试验共3272例患者,无tsDMARD试验符合标准。
  • 主要结局为ASAS40应答,次要结局包括各试验主要终点时的疾病活动度、功能和生活质量。
  • 计算症状持续时间较短与较长两组及各阈值(1-5年)的RR,并以b/tsDMARD组与安慰剂组RR之比计算RRR,采用随机效应荟萃分析合并效应。

主要发现

  • 2年阈值下,早期axSpA的ASAS40应答合并RR为2.04(95%CI 1.48-2.84),established疾病为2.28(95%CI 1.65-3.15)。
  • 2年阈值下RRR为0.89(95%CI 0.63-1.26),无统计学显著性。
  • 其他结局及3-5年其他症状持续时间阈值下,较短与较长症状持续时间之间的疗效无显著差异。

关键数值与推荐

  • ASAS共识将「早期axSpA」定义为症状持续时间≤2年,该定义源于专家意见,因证据有限。
  • 2年阈值下早期axSpA的ASAS40应答RR为2.04(95%CI 1.48-2.84),established疾病为2.28(95%CI 1.65-3.15),RRR为0.89(95%CI 0.63-1.26)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The ASAS consensus defines 'early axial spondyloarthritis (axSpA)' as symptom duration ≤2 years, a definition derived from expert opinion due to limited evidence. We performed a meta-analysis of randomized placebo-controlled trials (RCTs) of biologic and targeted synthetic DMARDs (bDMARDs/tsDMARDs) in axSpA to assess the impact of symptom duration on treatment response. METHODS: RCTs in adult axSpA patients comparing b/tsDMARDs to placebo were identified through systematic literature reviews supporting the ASAS-EULAR management recommendations. Primary outcome was ASAS40 response, with secondary outcomes including disease activity, function and quality of life at each trial's primary end point. Relative risks (RRs) comparing two groups (shorter vs longer symptom duration) were calculated for efficacy outcomes for each arm and for several thresholds of symptom duration (1-5 years). RR ratios (RRRs) were calculated as the ratio of RR of the b/tsDMARD and placebo arms. Pooled effects were obtained with random-effects meta-analysis. RESULTS: Eleven bDMARD RCTs, comprising 3272 axSpA patients, were included. No studies involving tsDMARDs met the eligibility criteria. At the 2-year threshold, pooled RR for ASAS40 response was 2.04 (95% CI, 1.48-2.84) in early axSpA and 2.28 (95% CI, 1.65-3.15) in established disease, yielding an RRR of 0.89 (95% CI, 0.63-1.26), with no statistical significance. There were no significant differences between efficacy in shorter and longer symptom duration for other outcomes or across other symptom duration thresholds (3-5 years). CONCLUSIONS: Based on a meta-analysis of 11 trials, no significant differences were found in the efficacy of bDMARDs compared with placebo in patients with axSpA with shorter vs longer symptom duration, across thresholds from 2 to 5 years.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Benavent D, Navarro-Compán V, Capelusnik D, et al. Does symptom duration impact on treatment response in axial spondyloarthritis? A meta-analysis of randomized controlled trials. Rheumatology (Oxford). 2025. PMID: 40644616. doi:10.1093/rheumatology/keaf382

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。